"We expect upside for shares on this derisking event," Wells Fargo says, referencing data...

|By:, SA News Editor

"We expect upside for shares on this derisking event," Wells Fargo says, referencing data released today by Celgene (CELG +7%) on Revlimid's performance in Phase III multiple myeloma trials. "We would remain buyers," analyst Brian Abrahams notes, adding that he "expects favorable detailed data at ASH."